Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthesis method of Daclatasvir

A synthesis method and technology of synthesis process, applied in the direction of organic chemistry, etc., can solve the problems of unsustainable response of patients, cumbersome treatment, adverse reactions, etc., and achieve the effects of cheap raw materials, simplified operation process, and little environmental pollution.

Inactive Publication Date: 2016-07-20
安徽联创生物医药股份有限公司
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current standard of care for HCV infection involves interferon-alpha alone or in combination with ribavirin, which is cumbersome and has debilitating or other serious adverse effects, and many patients do not consistently respond to treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis method of Daclatasvir
  • Synthesis method of Daclatasvir
  • Synthesis method of Daclatasvir

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] This embodiment relates to a synthetic method of daclatasvir, which consists of the following steps:

[0031] Step 1, the synthesis of intermediate 1

[0032] Dissolve 4.4-diacetylbiphenyl (40g, 0.17mol) and DIPEA (53g, 0.41mol) in 1000mL of dichloromethane, add TMSOTf (0.37mol) dropwise at 0°C, stir for 15 minutes after dropping, add NBS ( 0.39mol) of dichloromethane (200mL) solution, after dripping, stirred and reacted at 0°C for 2h, the reaction was complete, the system was poured into 500mL of water, layered, dried over anhydrous sodium sulfate, filtered with suction, concentrated to remove dichloromethane to obtain the intermediate 1 crude product, crystallized from toluene to obtain 61g solid, yield 91%;

[0033] MP: 224-226°C, 1 HNMR (400MHz, CDCl 3 ):δ(ppm):7.96-7.84(m,4H),7.61-7.52(m,4H),4.26(s,4H), HRMS(ESI):m / z[M+H] - 394.93.

[0034] Step 2, the synthesis of intermediate 2

[0035] Intermediate 1 (40g, 0.101mol) and L-proline derivative (60g, 0.222mol)...

Embodiment 2

[0040] This embodiment relates to a synthetic method of daclatasvir, which consists of the following steps:

[0041] Step 1, the synthesis of intermediate 1

[0042]Dissolve 4.4-diacetylbiphenyl (40g, 0.17mol) and DIPEA (49g, 0.38mol) in 1000mL of dichloromethane, add TMSOTf (0.39mol) dropwise at 0°C, stir for 15 minutes after dropping, add NBS ( 73g, 0.41mol) of dichloromethane (200mL) solution, after dripping, stirred and reacted at 0°C for 2h, the reaction was complete, the system was poured into 500mL of water, layered, dried over anhydrous sodium sulfate, suction filtered, concentrated to remove dichloromethane, to obtain The crude intermediate 1 was crystallized from toluene to obtain 62 g of solid, with a yield of 92%;

[0043] MP:224.5-226.5℃, 1 HNMR (400MHz, CDCl 3 ):δ(ppm):7.95-7.84(m,4H),7.62-7.52(m,4H),4.27(s,4H), HRMS(ESI):m / z[M+H] - 394.94.

[0044] Step 2, the synthesis of intermediate 2

[0045] Dissolve Intermediate 1 (40g, 0.101mol) and L-proline deriva...

Embodiment 3

[0050] This embodiment relates to a synthetic method of daclatasvir, which consists of the following steps:

[0051] Step 1, the synthesis of intermediate 1

[0052] Dissolve 4.4-diacetylbiphenyl (40g, 0.17mol) and DIPEA (0.39mol) in 1000mL of dichloromethane, add TMSOTf (91g, 0.41mol) dropwise at 0°C, stir for 15 minutes after dropping, add NBS ( 66g, 0.37mol) of dichloromethane (200mL) solution, after dripping, stirred and reacted at 0°C for 2h, the reaction was complete, the system was poured into 500mL water, layered, dried over anhydrous sodium sulfate, suction filtered, concentrated to remove dichloromethane, and obtained The crude intermediate 1 was crystallized from toluene to obtain 62 g of solid, with a yield of 92%;

[0053] MP: 225-226°C, 1 HNMR (400MHz, CDCl 3 ):δ(ppm):7.96-7.85(m,4H),7.60-7.52(m,4H),4.27(s,4H), HRMS(ESI):m / z[M+H] - 394.93.

[0054] Step 2, the synthesis of intermediate 2

[0055] Intermediate 1 (40g, 0.101mol) and L-proline derivative (60g,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a synthesis method of Daclatasvir. The method comprises the following steps: step 1, performing a bromination reaction on 4.4-diacetyl biphenyl which serves as a raw material so as to obtain an intermediate 1; step 2, performing a substitution reaction on the intermediate 1 so as to obtain an intermediate 2; step 3, performing a cyclization reaction on the intermediate 2 so as to finally obtain the Daclatasvir. Compared with reported synthesis routes, a synthesis route of the method has the following advantages that the route is short, and the yield is high; general means such as suction filtration, extraction and concentration are adopted for aftertreatment, and aftertreatment is simple and convenient; severe-pollution and high-toxicity reagents such as bromine are avoided, and a process of repeatedly using an acetic acid washing reaction system is avoided.

Description

technical field [0001] The invention relates to a synthesis method of hepatitis C virus NS5A inhibitor, in particular to a synthesis method of Daclatasvirdihydrocholide. Background technique [0002] Hepatitis C virus (HCV) is the main cause of chronic liver disease, and there is currently no vaccine to prevent HCV infection. The current standard of care for HCV infection involves interferon-alpha alone or in combination with ribavirin, which is cumbersome and has debilitating or other serious adverse effects, and many patients do not respond sustainably to treatment. Daclatasvir (Daclatasvirdihydrocholide), as a highly selective hepatitis C virus NS5A inhibitor, is a small molecule drug with direct antiviral effect, and it is also the first NS5A replication complex inhibitor for hepatitis C clinical use. [0003] In recent years, ShawnK.Pack (US7728027B2, published on June 01, 2010) and others have used 4.4-diacetylbiphenyl as raw material to obtain intermediate 1 through ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D403/14
CPCC07D403/14
Inventor 张中涛吴其华葛德培刘涛
Owner 安徽联创生物医药股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com